Skip to main content

Robert Wasserman

Articles From This Author

Allergan: Cramer's Top Takeaways
INVESTING
AGNTXMDOVAS

5 ways allergan can keep up momentum

By Robert Wasserman
Feb 15, 2017 3:03 PM EST
5 Stocks Hedge Funds Hate for 2016
STOCKS
OCLS

Skin in the game: This dermatology market stock is a good M&A bet

By Robert Wasserman
Nov 4, 2016 12:43 PM EDT
ICU Medical (ICUI) Stock Closed Higher on $1 Billion Pfizer Deal
OPINION
MD

How to invest in your favorite MD

By Robert Wasserman
Nov 2, 2016 11:02 AM EDT
Would You Meet This CEO for a 6:30 A.M. Interview?
STOCKS
TXMDFHCOJNP

Rebound may be in store for beaten-down shares of TherapeuticsMD

By Robert Wasserman
Oct 12, 2016 2:33 PM EDT
Immunotherapy Stocks Power Higher on Celgene-Juno Deal
STOCKS
MNTACHRS

Momenta, coherus biosciences are both good options in the biosimilar space

By Robert Wasserman
Oct 5, 2016 9:14 AM EDT
5 Best-Positioned Biotech Stocks on Brexit Volatility
OPINION
ENDPIPCI

Changes at the top for endo could benefit its smaller partners

By Robert Wasserman
Sep 26, 2016 9:03 AM EDT
Applied Genetic Technologies Is an Attractive Acquisition Target for Allergan or Biogen
STOCKS
AGNAGTCBIIB

Applied genetic technologies is an attractive acquisition target for allergan or biogen

By Robert Wasserman
Sep 20, 2016 9:05 AM EDT
Flexion's Latest FDA Approval Reignites Takeover Chatter
STOCKS
CTLTWSTIPCI

2 big companies and 1 small one to target in the pharma/biotech space

By Robert Wasserman
Sep 8, 2016 9:07 AM EDT
FDA deals blow to Endo over Opana ER Pain Med
STOCKS
ANIP

ANI Pharmaceuticals' varied offerings, strategic acquisitions make it a good play for investors

By Robert Wasserman
Aug 30, 2016 9:29 AM EDT
WebMD Puts Itself Up for Sale
STOCKS
EXAC

This little-known orthopedic-device stock is delivering huge returns

By Robert Wasserman
Aug 29, 2016 12:38 PM EDT
Changing Landscape for Generic-Drug Makers Creates Opportunities
INVESTING
IPXLSGNTMAYNF

Changing landscape for generic-drug makers creates opportunities

By Robert Wasserman
Aug 8, 2016 2:25 PM EDT
Opko Health, FireEye, KBR: 'Mad Money' Lightning Round
OPINION

Opko Health's many acquisitions add up to varied product offerings and potential growth

By Robert Wasserman
Aug 2, 2016 8:22 AM EDT
Valeant Acquires Eyegate Licensing Rights
OPINION
BMYONCECLLS

13 companies to watch from MIT's smart 50 list, including 4 buys

By Robert Wasserman
Jul 21, 2016 7:48 AM EDT
NxStage Medical Acquired by Fresenius for $2 Billion
OPINION
NEO

NeoGenomics deal with GE's Clarient 6 months later: boom or bust?

By Robert Wasserman
Jul 6, 2016 10:38 AM EDT
Opko Health, FireEye, KBR: 'Mad Money' Lightning Round
OPINION
OPK

Opko is a buying opportunity after FDA's approval of kidney drug

By Robert Wasserman
Jun 30, 2016 5:15 PM EDT